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Abstract: Dendritic cell (DC) vaccines are a promising and potent therapeutic tool for chronic diseases, autoimmune diseases, and
cancer because of the unique ability of DCs to stimulate T cells. The challenge of DC vaccines is to find an effective form for antigen
presentation. Although pure antigens, antigen complexes, plasmids, and mRNA have been used in different studies, no proper application
to overcome this problem has been found yet. In this study, we investigated the eligibility of a commercial hepatitis B virus (HBV)
vaccine or a vaccine–monoclonal antibody complex for antigen loading of DCs for a therapeutic purpose. DCs were derived from the
bone marrow of transgenic hepatitis B (HBV-tg) mice using a granulocyte macrophage-colony stimulating factor and interleukin-4,
and then loaded with a commercial HBV vaccine (containing hepatitis B virus surface antigens and aluminum hydroxide adjuvant) or a
vaccine–antibody complex. HBV-tg mice were immunized with the vaccine and vaccine–antibody loaded DCs. Optimum HBV vaccine
concentration and loading time were determined by 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST1) methods. Therapeutic effects of vaccine–antibody loaded DCs were determined by the evaluation of antibody response and hepatitis
B surface expression levels in HBV-tg mice. Our results showed that commercial HBV vaccine loaded DCs induced humoral response
in HBV-tg mice but had no effect on cellular immunity.
Key words: Dendritic cell vaccine, hepatitis B virus, immunotherapy

1. Introduction
Dendritic cells (DCs) have a critical role for stimulating
innate and adaptive immunity. When DCs are present in
peripheral tissue, they encounter and engulf the infectious
agents, and they start antigen processing, mature, and
migrate to lymph nodes for stimulating naive T cells.
T cell activation, especially that of the cytotoxic T cell
(Tc), is crucial to overcome the immune tolerance in
chronic diseases and cancer. Therefore, DC vaccines are
an alternative approach for cell-based immunotherapy
(1–5). DCs generally have been derived from peripheral
mononuclear cells of human blood or spleen or bone
marrow in animal models (6–8), and different methods
can be used for loading them. Despite a large number of
DC vaccine studies, only one study was approved by the
Food and Drug Administration (FDA), which consists of
not only DCs but also other antigen presenting cells (9).
Studies for treatment of chronic hepatitis B constitute
a crucial part of DC vaccine research. Despite the use of
the commercial prophylactic vaccine since 1981, hepatitis
B virus (HBV) infection is still a serious health problem
* Correspondence: ibrahim.hatipoglu@tubitak.gov.tr

all over the world. The World Health Organization
(WHO) indicates that 370 million people are chronically
infected with HBV worldwide and each year 1 million
people die because of HBV-related diseases (10). Type I
interferons and nucleotide analogues have been used for
the treatment of chronic HBV infection, but the methods
of interest are expensive and their success rate is rather
low. Furthermore, nucleotide analogues may lead to the
development of resistant types of HBV (11–14). Therefore,
the DC vaccines are thought to be an alternative method
for treatment and have been used in clinical and animal
models. In DC vaccine studies, immature DCs have been
loaded with various concentrations of hepatitis B surface
antigen (HBsAg), hepatitis B virus c antigen (HBcAg), or
complexed other proteins. The experiments have shown
that DC vaccines evoke an effective immune response, but
the stimulation of immune response in hepatitis B virus e
antigen (HBeAg) positive patients is difficult. Thus, more
effective loading methods are necessary (15–19).
In the present study, our aim is to overcome HBV
tolerance in chronic hepatitis B transgenic (HBV-tg)
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mice by using a vaccine or vaccine–antibody complex
loaded DCs. Akbar et al. showed that commercial HBV
vaccines can be used as a source of HBsAg (20); however,
the vaccine–antibody complex has not been tested before.
The positive effect of antigen–antibody complexes on
immunity has been proven by many laboratories. The Fc
region of the antibody from the vaccine–antibody complex
binds Fc receptors on DCs and enhances antigen uptake,
which also improves antigen presentation and Tc response
(21–24).
In this study, optimum vaccine dose, incubation time,
and DC number were determined by 2-(4-iodophenyl)3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium
(WST-1) cell viability test. DCs were loaded with optimum
vaccine or vaccine–antibody complex and HBV-tg mice
were immunized twice, intraperitoneally. Therapeutic
effects of DC vaccines were determined by investigating
humoral and cellular immune responses. Results have
shown that vaccine loaded DCs significantly induce antiHBsAg response but have no effect on cellular immunity.
2. Materials and methods
2.1. Mice
HBV-tg mice were prepared at the Genetic Engineering
and Biotechnology Institute of the TÜBİTAK Marmara
Research Center as reported before (25), and mice of
6 to 10 weeks old were used in this study. HBsAg is
constitutively expressed in transgenic mice and liver
HBV DNA, and HBsAg was detected in the sera and
livers of HBV-tg mice. All mice were housed under
specific pathogen free conditions. Animal experiments
were approved by the Ethics Committee of the Genetic
Engineering and Biotechnology Institute of the TÜBİTAK
Marmara Research Center.
2.2. Generation of dendritic cells and immunization
Bone marrow derived DCs were generated as described
previously with minor modifications (7). Briefly, bone
marrow cells were removed from the femurs of HBV-tg
mice and erythrocytes were depleted by using ammonium
chloride solution. After counting, the cells (1 × 106/
mL) were seeded onto 10-cm petri dishes in RPMI 1640
medium (Gibco Life Sciences, USA) containing 10 mM
N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic
acid
(HEPES), 10 µg/mL gentamicin, 100 U/mL penicillin, 100
µg/mL streptomycin, 10% fatal bovine serum (FBS), 1%
MEM nonessential amino acids, 50 µM β-mercaptoethanol,
20 ng/mL recombinant murine granulocyte/macrophagecolony stimulating factor (mGM-CSF, Gibco Life Sciences),
and mouse interleukin-4 (mIL-4, 200 IU/ml, Gibco)
and incubated. Every 3 days, two-thirds of the medium
was replaced with fresh medium. On day 6, cells were
harvested by treating with versene solution (Invitrogen,
USA) and DCs were seeded into 6-well culture plates as
1.5 × 106 cells per well, and 100 U/mL rTNF-α was added
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in addition to mGM-CSF and IL-4. Twenty-four hours
later, the DCs were activated by adding 125 µL vaccine,
125 µL vaccine–antibody complex, and monoclonal
antibody (MAb) (5 µg/3.5 mL). Lipopolysaccharide (100
ng/mL) and CpG 1826 (1 µg/well) were also added to each
well. Cells were harvested 5 h later and 5 × 105 DCs were
prepared for immunization in 100 µL PBS. Four mice were
used in each group and immunizations were performed
intraperitoneally twice at weekly intervals with a DC
vaccine.
2.3. Flow cytometric analysis
Cells were harvested from petri dishes on day 6 and
washed with PBS. The phenotype of the cells was evaluated
using fluorochrome-conjugated antibodies, anti-CD11cPE and anti-CD11b IFTC (BD, USA), and relevant isotype
controls were always used. Cells were stained with labeled
antibodies for 20 min at 4 °C and washed with cold PBS,
and were then suspended in PBS. Data was acquired using
the FACScan instrument (BD Biosciences, USA) and
analyzed using the Cellquest program.
2.4. Generation of vaccine–antibody complex
Commercial HBV vaccine (Gen Hevac), which contains
40 µg/mL HBsAg, was incubated with anti-HBsAg
monoclonal antibody (2G3) at a 2:1 (m/m) ratio for 1 h
at 37 °C, then incubated at room temperature overnight.
Anti-HBsAg MAb was produced in our laboratory with
hybridoma technology as reported previously (26).
2.5. WST-1 assay
This assay is based on the cleavage of the WST salt to soluble
formazan by mitochondrial dehydrogenases in viable cells.
On day 6, immature dendritic cells were seeded as 5 × 104
or 2.5 × 104 cells per well of 96-well plates in 100 µL. After
24 h of incubation, DCs were loaded with 3.6 µL (144
ng HBsAg) or 0.72 µL (28 ng HBsAg) vaccine, vaccine–
antibody complex, and hydrogen peroxide (10 µL/well) for
5, 24, and 48 h at 37 °C. At the end of the incubation, 10
µL/well WST-1 (Roche, Germany) was added to each well,
and then the plates were incubated for an additional 2 h at
37 °C. The absorbance was measured at 450 nm.
2.6. Serological assays
Antibody response to HBsAg was measured by indirect
ELISA. Microtiter ELISA plates were coated with HBsAg
(Fitzgerald, USA; 400 ng/mL) in PBS at 4 °C by overnight
incubation. After washing and blocking, the diluted
mouse serum was added to each well and incubated for
1 h at 37 °C. The wells were washed and bound antibody
was detected with alkaline phosphate conjugated goat
antimouse polyvalent antibody (Sigma, at 1/1000 dilution)
by incubation at 37 °C for 1 h. Plates were then washed
and para-nitrophenylphosphate (PNPP) at 1 mg/mL in
substrate buffer (0.1 M glycine, pH 10.4; 1 mM ZnCl2; and
1 mM MgCl2) was added, and the absorbance at 405 nm
was measured.
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2.7. RNA isolation and quantitative RT-PCR analysis
Liver tissues (50–100 mg) were collected from animals
and used for RNA isolation. After decapitation, tissues
were immediately collected, shock-frozen in liquid
nitrogen, and stored at –80 °C until preparation of RNA
samples. Total RNA from liver tissues of each mouse
was extracted using TRIzol reagent (Invitrogen, USA),
chloroform, and isopropanol. cDNA synthesis was
carried out using 1 µg whole RNA sample with a Roche
Transcriptor High Fidelity cDNA Synthesis Kit according
to the manufacturer’s protocol. The primer sequence for
the HBs gene of the HBV virus was designed using the
Primer 3 program as listed in Table 1. Real-time RT-PCR
was performed using the QIAGEN SYBR Green Supermix
Kit (QIAGEN, USA) for the selected gene in a Bio-Rad iQ5
thermal cycler (Bio-Rad Laboratories, USA) according to
the manufacturer’s instructions. All data were analyzed
using the Relative Expression Software Tool (REST 2009
Software, 12/2009, http://rest.gene-quantification.info).
The standard REST 2009 algorithm calculates efficiency
using the slope from the best-fit standard curve as follows:
E = 10–1/slope – 1. The slope value derived from Ct values
of serially diluted samples was automatically calculated
by Bio-Rad iQ5 thermal cycler. The estimations of each
sample’s expression ratio, an intermediate absolute
concentration value, was calculated using the following
formula: concentration = Etarget∆Cp target (MEAN control – MEAN sample).
The relative expression of each target gene was calculated
by the ratio of the concentration of the target gene to the
geometric mean of all reference gene concentrations.
2.8. Statistical analysis
Differences between the groups were analyzed by oneway ANOVA (Tukey’s test) using SPSS 15.0 (IBM, USA).
Values were considered to be statistically significant when
P < 0.05.
3. Results
3.1. Dendritic cell generation
DCs were derived from mouse bone marrow using GMCSF and IL-4. On day 6, flow cytometric analyses showed
that the frequency of DCs expressing CD 11c+ CD11b+ was
about 80%–85%.
3.2. Determination of the viability of DCs loaded with
vaccine and vaccine–antibody complex
To determine the optimum concentration of vaccine for
loading of DCs, the WST-1 test was performed. For this,

5 × 104 or 2.5 × 104 DCs were treated with 3.6 µL or 0.72
µL vaccine, vaccine–antibody complex, and antibody for 5
h, 24 h, and 48 h. The control group was not treated with
a vaccine or antibody. After exposure of all wells, 10 µL of
the WST-1 solution was added and incubated for 2 h at 37
°C. The optical density of the solubilized formazan product
was determined using a spectrophotometer with a 450-nm
and 695-nm ﬁlter as a reference. The control group was
accepted as 100% live, and cell viability of other groups
was determined using the proportion of their absorbance
value to the control group. Tables 2 and 3 show the viability
of DCs after 24 h and 48 h, treated with 3.6 µL containing
vaccine or vaccine–antibody complex, respectively. It was
found that the viability of cells decreased by about 50%
with respect to the cell number in these groups. Tables 4
and 5 show the viability of DCs treated with 0.72 µL HBsAg
containing vaccine and vaccine antibody for 24 h and 48 h.
We found that this amount of HBsAg is less cytotoxic than
3.6 µL HBsAg, but it contains nearly less than 5 times the
HBsAg. For increasing the percentage of loaded DC, 5 ×
104 DCs were loaded with 3.6 µL HBsAg containing vaccine
or vaccine–antibody complex for 5 h, and cell viability was
found at 77 ± 7% and 74 ± 13% respectively (Table 6). This
experimental protocol was chosen and adapted for vaccine
or vaccine-antibody complex immunizations in HB-tg
mice.
3.3. Detection of immune response in DC immunized mice
To determine the effect of the HBV vaccine, HBV-tg
mice (n = 4) were immunized with vaccine, vaccine–
antibody, and antibody loaded and unloaded DCs 2 times,
intraperitoneally. The concentration of loaded vaccine and
vaccine–antibody complex was determined according
to WST-1 test results. The WST-1 test was performed
in a 96-well plate, but DCs were loaded in 6-well plates
for immunization and DC number and the vaccine and
vaccine–antibody complex concentration were increased
in accordance with the volume of medium in the well.
HBV-tg mice sera were collected 3 weeks after the
second immunization. An ELISA test was performed to
detect anti-HBsAg levels in mice. We found that all DC
immunized mice had an induced anti-HBsAg response,
but vaccine loaded DCs induced better antibody response
compared to others. The anti-HBsAg level in this group
was nearly 3 times higher than in control groups (Figure).
As is generally accepted, the liver is the primary site
of HBV infection (27). A decrease in HBs gene expression

Table 1. Primer sequences for RT-qPCR.
Primers

Nucleotide sequence

Expected size (bp)

HBs gene

Forward 5’ CCTCTTCATCCTGCTGCTAT 3’
Reverse 5’ CCACTCCCATAGGAATCTTG 3’

247

459
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Table 2. Incubation of 5 × 104 DCs for 24 and 48 h with 3.6 µL vaccine or vaccine–antibody complex;
10 µL hydrogen peroxide was used as a positive control. The experiments were performed in triplicate.
5 × 104 DCs

Quantity

Vaccine

3.6 µL

Vaccine-MAb

3.6 µL

Hydrogen peroxide

10 µL

Incubation time

Cell viability (% of control)

24 h
48 h
24 h
48 h
24 h
48 h

49 ± 3
48 ± 6
49 ± 6
43 ± 6
9±5
5±1

Table 3. Incubation of 5 × 104 DCs for 24 and 48 h with 0.72 µL vaccine or vaccine–antibody complex;
10 µL hydrogen peroxide was used as a positive control. The experiments were performed in triplicate.
5 × 104 DCs

Quantity

Vaccine

0.72 µL

Vaccine-MAb

0.72 µL

Hydrogen peroxide

10 µL

Incubation time

Cell viability (% of control)

24 h
48 h
24 h
48 h
24 h
48 h

93 ± 3
65 ± 6
94 ± 6
74 ± 6
9±5
5±1

Table 4. Incubation of 2.5 × 104 DCs for 24 and 48 h with 3.6 µL vaccine or vaccine–antibody complex;
10 µL hydrogen peroxide was used as a positive control. The experiments were performed in triplicate.
2.5 × 104 DCs

Quantity

Vaccine

3.6 µL

Vaccine-MAb

3.6 µL

Hydrogen peroxide

10 µL

Incubation time

Cell viability (% of control)

24 h
48 h
24 h
48 h
24 h
48 h

53 ± 11
58 ± 13
54 ± 17
55 ± 8
9±3
4±1

Table 5. Incubation of 2.5 × 104 DCs for 24 and 48 h with 0.72 µL HBsAg containing vaccine or vaccine–
antibody complex; 10 µL hydrogen peroxide was used as a positive control. The experiments were
performed in triplicate.
2.5 × 104 DCs

Quantity

Vaccine

0.72 µL

Vaccine-MAb

0.72 µL

Hydrogen peroxide

10 µL

was expected after stimulation of T cell response in the
liver. HBs gene expression level in HBV-tg mice liver was
determined by RT-qPCR, but there was no difference
between the groups (Table 7).
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Incubation time

Cell viability (% of control)

24 h
48 h
24 h
48 h
24 h
48 h

68 ± 5
66 ± 8
68 ± 10
58 ± 2
9±3
4±1

4. Discussion
Discovery of the DC immune effect in the early 1970s was
the milestone in DC studies (2). Following studies have
shown that DCs have an important role in innate and
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Table 6. Incubation of 5 × 104 DCs for 24 and 48 h with 3.6 µL vaccine or vaccine–antibody complex.
The experiments were performed in triplicate.
5 × 104 DCs

Quantity

Incubation time

Cell viability (% of control)

Vaccine
Vaccine-MAb

3.6 µL
3.6 µL

5h
5h

77 ± 7
74 ± 13

1.2
1.0
OD 405 nm

adaptive immune response, especially in T cell response.
DC vaccines are promising alternative therapeutic
methods to overcome immune tolerance. A large number
of DC vaccine studies have been performed for more than
30 years, but there are no exact protocols and more studies
are necessary. The method for loading DCs is a special
issue in DC vaccine studies. Purified antigens, tumor
lysate, viral vectors, mRNA, or DNA have been used for
loading the DCs (17,28–31).
In the current study, the HBV vaccine, which consists of
HBsAg and aluminum hydroxide adjuvant, was used as an
alternative source for HBsAg. The vaccine was complexed
with anti-HBsAg for enhancing loading success. We
determined the optimum loading concentrations of vaccine
for DCs by WST-1 cell viability assay due to the potential
cytotoxic effect of the vaccine (32–34). We found that 125
µL vaccine was the optimal dose for 5 h of incubation.
After deciding the optimal vaccine concentration, DCs
were loaded with vaccine or vaccine–antibody complex
and HBV-tg mice were immunized. Before our study,
Akbar et al. showed that HBV vaccine loaded human
peripheral blood DCs induce anti-HBsAg response and T
cell proliferation in HBV vaccine nonresponders (20), and
Flach et al. immunized alum pretreated DCs to C57BL/6
mice along with OVA and induced anti-OVA immune
response (35). However, in our study, vaccine loaded DCs
were used with a therapeutic purpose in HBV-tg mice for
the first time.
After the second immunization, anti-HBsAg response
was followed for 3 weeks in the groups. Only vaccine
loaded DCs induced significant humoral response. This
result is correlated with those of Akbar et al. and Flach
et al. (20,35). However, we did not find any significant
antibody response in mice immunized with the vaccine–
antibody complex loaded DCs. Alum binds lipids of DC

*

*
Week 1

0.8

Week 2

Week 3

0.6
0.4
0.2
0.0

Control

DC+
Vaccine

DC+Vaccine
-MAb

DC+MAb

DC

Figure 1. Humoral immune response. Antibody response in sera
of HBV-tg mice immunized with vaccine, vaccine–antibody,
and antibody loaded and nonloaded DCs. DC+Vaccine: vaccine
loaded DCs, DC+Vaccine-MAb: vaccine–antibody complex
loaded DCs, DC+MAb: antibody loaded DCs, DC: nonloaded
DCs. The experiments were performed in quadruplicate and
results are shown as mean ± standard deviation. *: P < 0.05

(35). This mechanism may inhibit Fc receptor mediated
phagocytosis and effects of the vaccine–antibody complex
on humoral immune response.
Three weeks after the second immunization, decrease
of HBs gene expression was not observed. These results
can be related to T cell stimulation capacity of the vaccine
or vaccine-antibody loaded DCs. Although aluminum
adjuvant generally induces a protective immune response,
the mechanism of action of aluminum adjuvant on the
immune system and DCs is still being investigated (35–
39). While some studies indicated that alum adjuvant did
not induce expression of CD40, CD80, CD86, or major
histocompatibility complex class II, others showed that
expression of CD86 receptor was induced (37,38). In
our study, we found that there were no differences in the

Table 7. HBs gene expression profile 3 weeks after the last immunization in DC immunized groups. The experiments were
performed in quadruplicate and results are shown as mean ± standard deviation.
Pairwise comparison
Control/DC+Vaccine
Control/DC+Vaccine-MAb
Control/DC+MAb
Control/DC

Fold change Expression
1.36
1.23
1.03
1.08

Upregulated in DC+Vaccine sample group
Upregulated in DC+Vaccine-MAb sample group
Upregulated in DC+MAb sample group
Upregulated in DC sample group

P-value
0.45
0.54
0.93
0.81
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expression levels of CD40, CD80, and CD86 (data not
shown).
In our study, we showed that HBV vaccine loaded
DCs induced humoral response. We also showed that
depending on the concentration of vaccine and incubation
time, the vaccine might have a cytotoxic effect on DCs. We
believe that DC vaccine studies will be more important in
the future and that the major proof of the idea will lie in
phase studies.
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